Radium Ra 223 dichloride (Xofigo®) in Castrate-Resistant Prostate Cancer (CRPC)

Download PQI pdf 1.45MB

Last Updated: December 1, 2024

By: First Urology, KY | Comprehensive Cancer Centers of Nevada, NV

About this PQI in Action

This PQI in Action is a follow up to the Radium Ra 223 Dichloride (Xofigo) Management PQI and explores how the medically integrated teams at First Urology and Comprehensive Cancer Centers of Nevada (CCCN) collaborate and utilize the information found in the PQI as part of their daily practice. This PQI in Action focuses on the use of radium-223 in patients with CRPC.

Frequently Searched

Supported by

Radium Ra 223 dichloride (Xofigo®) in Castrate-Resistant Prostate Cancer (CRPC)

About this PQI in Action

More About This PQI in Action

PQI: Radium Ra 223 Dichloride (Xofigo®) Management